Bee Venom Allergy Clinical Trial
Official title:
Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.
| Verified date | March 2013 |
| Source | Allergopharma GmbH & Co. KG |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Germany: Paul-Ehrlich-Institut |
| Study type | Interventional |
The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | April 2010 |
| Est. primary completion date | January 2005 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - History of bee venom allergy, - Positive RAST for bee venom, - Positive skin prick test for bee venom Exclusion Criteria: - Serious chronic diseases |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Germany | Allergopharma GmbH & Co. KG | Reinbek |
| Lead Sponsor | Collaborator |
|---|---|
| Allergopharma GmbH & Co. KG |
Germany,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04259359 -
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
|
||
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A |